Position
Creative Planning in ARS Pharmaceuticals, Inc.
Back to the book · All holders of SPRY
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$87.9K$11.65 → $8.03
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 25.3K | $295.1K | — | — | — | 0.0% |
| Q1 2026 | 24.3K | $194.9K | $8.03 | −$87.9K | −$12.3K | 0.0% |